 |
|
|
| |
Predictors of Sustained Virologic Response in 21,242 Genotype 1 Patients Treated with Ledipasvir/Sofosbuvir±Ribavirin or Ombitasvir/Paritaprevir/Ritonavir+Dasabuvir±Ribavirin
in Routine Medical Practice
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Lisa Backus*, MD PhD1,2, Pamela Belperio, PharmD1,3, Troy Shahoumian MPH PhD1, Timothy P. Loomis PhD1 and Larry Mole PharmD1
1Patient Care Services/Population Health, Department of Veterans Affairs, 2 Veterans Health Administration Palo Alto, 3 Veterans Health Administration Los Angeles
|
| |
|
|
|
|
|
